Cargando…

Impact of the influenza vaccine on COVID-19 infection rates and severity

BACKGROUND: With a unique influenza season occurring in the midst of a pandemic, there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. METHODS: In this retrospective cohort study, patients receiving a laboratory test for COVID-19 were identified. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Conlon, Anna, Ashur, Carmel, Washer, Laraine, Eagle, Kim A., Hofmann Bowman, Marion A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899024/
https://www.ncbi.nlm.nih.gov/pubmed/33631305
http://dx.doi.org/10.1016/j.ajic.2021.02.012
_version_ 1783653985064845312
author Conlon, Anna
Ashur, Carmel
Washer, Laraine
Eagle, Kim A.
Hofmann Bowman, Marion A.
author_facet Conlon, Anna
Ashur, Carmel
Washer, Laraine
Eagle, Kim A.
Hofmann Bowman, Marion A.
author_sort Conlon, Anna
collection PubMed
description BACKGROUND: With a unique influenza season occurring in the midst of a pandemic, there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. METHODS: In this retrospective cohort study, patients receiving a laboratory test for COVID-19 were identified. The primary outcome was comparison of positive COVID-19 testing in those who received the influenza vaccine versus those who did not. Secondary end points in patients testing positive for COVID-19 included mortality, need for hospitalization, length of stay, need for intensive care, and mechanical ventilation. RESULTS: A total of 27,201 patients received laboratory testing for COVID-19. The odds of testing positive for COVID-19 was reduced in patients who received an influenza vaccine compared to those who did not (odds ratio 0.76, 95% CI 0.68-0.86; P < .001). Vaccinated patients testing positive for COVID-19 were less likely to require hospitalization (odds ratio, 0.58, 95% CI 0.46-0.73; P < .001), or mechanical ventilation (odds ratio, 0.45, 95% CI 0.27-0.78; P  = .004) and had a shorter hospital length of stay (risk ratio, 0.76, 95% CI 0.65-0.89; P < .001). CONCLUSION: Influenza vaccination is associated with decreased positive COVID-19 testing and improved clinical outcomes and should be promoted to reduce the burden of COVID-19.
format Online
Article
Text
id pubmed-7899024
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.
record_format MEDLINE/PubMed
spelling pubmed-78990242021-02-23 Impact of the influenza vaccine on COVID-19 infection rates and severity Conlon, Anna Ashur, Carmel Washer, Laraine Eagle, Kim A. Hofmann Bowman, Marion A. Am J Infect Control Major Article BACKGROUND: With a unique influenza season occurring in the midst of a pandemic, there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. METHODS: In this retrospective cohort study, patients receiving a laboratory test for COVID-19 were identified. The primary outcome was comparison of positive COVID-19 testing in those who received the influenza vaccine versus those who did not. Secondary end points in patients testing positive for COVID-19 included mortality, need for hospitalization, length of stay, need for intensive care, and mechanical ventilation. RESULTS: A total of 27,201 patients received laboratory testing for COVID-19. The odds of testing positive for COVID-19 was reduced in patients who received an influenza vaccine compared to those who did not (odds ratio 0.76, 95% CI 0.68-0.86; P < .001). Vaccinated patients testing positive for COVID-19 were less likely to require hospitalization (odds ratio, 0.58, 95% CI 0.46-0.73; P < .001), or mechanical ventilation (odds ratio, 0.45, 95% CI 0.27-0.78; P  = .004) and had a shorter hospital length of stay (risk ratio, 0.76, 95% CI 0.65-0.89; P < .001). CONCLUSION: Influenza vaccination is associated with decreased positive COVID-19 testing and improved clinical outcomes and should be promoted to reduce the burden of COVID-19. The Author(s). Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. 2021-06 2021-02-22 /pmc/articles/PMC7899024/ /pubmed/33631305 http://dx.doi.org/10.1016/j.ajic.2021.02.012 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Major Article
Conlon, Anna
Ashur, Carmel
Washer, Laraine
Eagle, Kim A.
Hofmann Bowman, Marion A.
Impact of the influenza vaccine on COVID-19 infection rates and severity
title Impact of the influenza vaccine on COVID-19 infection rates and severity
title_full Impact of the influenza vaccine on COVID-19 infection rates and severity
title_fullStr Impact of the influenza vaccine on COVID-19 infection rates and severity
title_full_unstemmed Impact of the influenza vaccine on COVID-19 infection rates and severity
title_short Impact of the influenza vaccine on COVID-19 infection rates and severity
title_sort impact of the influenza vaccine on covid-19 infection rates and severity
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899024/
https://www.ncbi.nlm.nih.gov/pubmed/33631305
http://dx.doi.org/10.1016/j.ajic.2021.02.012
work_keys_str_mv AT conlonanna impactoftheinfluenzavaccineoncovid19infectionratesandseverity
AT ashurcarmel impactoftheinfluenzavaccineoncovid19infectionratesandseverity
AT washerlaraine impactoftheinfluenzavaccineoncovid19infectionratesandseverity
AT eaglekima impactoftheinfluenzavaccineoncovid19infectionratesandseverity
AT hofmannbowmanmariona impactoftheinfluenzavaccineoncovid19infectionratesandseverity